Actavis (NYSE: ACT) is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.
The Company has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.
Actavis markets approximately 1000 generic, branded generic, established brands and Over-the-Counter (OTC) pharmaceutical products globally through operations in more than 60 countries.
The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.
Publications 63 show all
- 6Pulmonary Disease, Chronic Obstructive/drug therapy
- 3Aminopyridines/therapeutic use
- 3Anxiety Disorders/drug therapy
- 3Benzamides/therapeutic use
- 2Alzheimer Disease/drug therapy
- 2Anti-Bacterial Agents/administration & dosage
- 2Anti-Bacterial Agents/adverse effects
- 2Anti-Bacterial Agents/pharmacokinetics
Patents 17,051show all
Clinical Trials 809show all
SEC Filings show all